166 related articles for article (PubMed ID: 38331776)
1. Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis.
Wang Y; Ren H
BMC Cancer; 2024 Feb; 24(1):187. PubMed ID: 38331776
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effect of endostar on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells].
Shang L; Zhao J; Wang W; Xiao W; Li J; Li X; Song W; Liu J; Wen F; Yue C
Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):722-9. PubMed ID: 25342038
[TBL] [Abstract][Full Text] [Related]
3. Endostar Synergizes with Radiotherapy to Inhibit Angiogenesis of Cervical Cancer in a Subcutaneous Xenograft Mouse Model.
Xu Z; Zhao X; Shu H; Luo W; Dong Y; Xu L; Zhu H; Zhao Q; Lv Y
Front Biosci (Landmark Ed); 2022 Aug; 27(8):238. PubMed ID: 36042171
[TBL] [Abstract][Full Text] [Related]
4. Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism.
Ni Q; Ji H; Zhao Z; Fan X; Xu C
Eur J Pharmacol; 2009 Jul; 614(1-3):1-6. PubMed ID: 19389394
[TBL] [Abstract][Full Text] [Related]
5. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms.
Wu H; Deng J; Yu S; Wang X; Chen Y
J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):108-12. PubMed ID: 20155466
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
[TBL] [Abstract][Full Text] [Related]
9. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
Song Z; Jia G; Ma P; Cang S
Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of METTL14-mediated m
Gong S; Wang S; Shao M
J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
[TBL] [Abstract][Full Text] [Related]
11. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
12. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
Hu Y; Zhou Z; Luo M
Medicine (Baltimore); 2022 Dec; 101(52):e32207. PubMed ID: 36595983
[TBL] [Abstract][Full Text] [Related]
14. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis of SCLC inhibited by decreased expression of FMOD via downregulating angiogenic factors of endothelial cells.
Ao Z; Yu S; Qian P; Gao W; Guo R; Dong X; Xu J; Zhang R; Jiang C; Ji F; Qian G
Biomed Pharmacother; 2017 Mar; 87():539-547. PubMed ID: 28081464
[TBL] [Abstract][Full Text] [Related]
16. Bronchoscopic intratumoral injections of cisplatin and endostar as concomitants of standard chemotherapy to treat malignant central airway obstruction.
Jiang W; Yang X; Wang X; Li Y; Yang X; Wang N; Yin B
Postgrad Med J; 2022 Feb; 98(1156):104-112. PubMed ID: 33070116
[TBL] [Abstract][Full Text] [Related]
17. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
Rong B; Yang S; Li W; Zhang W; Ming Z
World J Surg Oncol; 2012 Aug; 10():170. PubMed ID: 22917490
[TBL] [Abstract][Full Text] [Related]
19. METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.
Zhang Y; Liu S; Zhao T; Dang C
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34132367
[TBL] [Abstract][Full Text] [Related]
20. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
